Table 1 Antiretroviral therapy and drug resistance mutation over time in study subjects
Patient | Year | Antiretroviral therapy | mutations associated with resistance | Virus load Copies/ml | |
|---|---|---|---|---|---|
M | 1993 | AZT | n.d. | ||
1995 | AZT, 3TC | ||||
12/1997 | d4T, 3TC | ||||
1999 | 4700 | ||||
07/2004 | RT: M41L, M184V, T215Y, (T39A, V60I, D121Y, I135T, I142V1, D177G, V179I, T200A, Q207E, L214f, L228H, Q334H) | 26929 | |||
PR: L63P, I13V, (V3I, K14R, S37N) | |||||
CS p1/p6-gag: L449V, S451N | |||||
08/2004 | ATV/r, EFV | ||||
01/2005 | < 50 | ||||
04/2005 | ATV/r, EFV, 3TC | < 50 | |||
W | 08/2006 | RT: M41L, T215D, (T39A, V60I, D121Y,135T,N137S,I142V, S162C, I202I/V, Q207E/K, l214F, l228H) | > 500.000 | ||
PR: L63P, I13V, (E35D, S37N/S, S37N, V3I) | |||||
CS p1/p6-gag: L449V, S451N | |||||
09/2006 | TVd, INV/r | ||||
10/2008 | TVd, ATV/r | < 40 | |||
11/2008 | 1381 | ||||
12/2008 | 132 | ||||
02/2008 | 8515 | ||||
03/2009 | RT: M41L, T215D, (T39A,V601I D121Y, K122E,135T,N137S,I142V S162C, I202IV, Q207E/K, L214F, L228H, V245M, A272P, T286A, E297K) | ||||
PR: L63P, I13V, E35D | |||||
CS p1/p6-gag: l449V, S451N | |||||
04/2009 | NVP, DRV/r | ||||
06/2009 | < 40 | ||||
11/2009 | < 40 | ||||